University of California Irvine, (UCI) recently announced their participation in a COVID-19-focused clinical trial investigating a drug called Aviptadil in at risk patients. Dr. Richard Lee, Interim chief of UCK Health Division of Pulmonary Diseases and Critical Care Medicine, as well as principal investigator for the clinical trial, commented that “This study will focus on patients for whom mortality is alarmingly high.” What is the drug? Who is the study’s sponsor? What is the nature of the COVID-19 study?
TrialSite News sought to evaluate this study and actually uncovered two studies the sponsor is leading that investigate the use of Aviptadil.
What is Aviptadil?
According to the National Institutes of Health (NIH), Aviptadil is an injectable formulation of vasoactive intestinal polypeptide (VIP) in combination with adrenergic drug phentolamine. Interestingly, the initial focus was alternatives to erectile dysfunction (combining Aviptadil with phentolamine and sexual stimulation) as the combination was free of major side effects and cumbersome delivery methods which limit the use of other pharmacologic preparations.
What is a vasoactive intestinal polypeptid...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).